Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer
Read moreThe MAF Test® is now available to oncologists and pathologists in South Korea and will benefit an estimated 34,000 new patients each year
Read moreThe SICC Innvierte fund of CDTI Innovación invests in InceptionBio, a fund aimed at promoting the creation of biotechnology companies and the development of early-stage technology transfer projects.
Read moreCE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data
Read moreProceeds to support the advancement of three first- and best-in-class ADC programs through upcoming clinical milestones
Read moreInceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. The fund will primarily invest in technology transfer oppor...
Read moreJoan Perelló and Arturo Urrios will lead a new vertical focused on company creation and early-stage biotech projects, with a strong focus on Spain.
Read moreStrategic research collaboration to advance MTx’s recombinant polyclonal IgG technology
Read moreSparingVision, a clinical-stage genomic medicine company transforming the treatment of retinal diseases, today announced that it has successfully completed dosing in its Phase I/II PRODYGY clinical tr...
Read moreLa estrategia de inversión especializada ha permitido capitalizar el gran potencial de la innovación biomédica, impulsada además por una oleada de fusiones y adquisiciones.
Read moreInbiomotion has announced that its MAF Test® has been included in the 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, a key consensus document guiding clinical deci...
Read moreComplete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment
Read more